Corporate Overview & Strategy

Universal Biosensors (UBI) is focused on the research, development and manufacture of diagnostic test systems for point-of-care (POC) professional and home use. The point-of-care diagnostic market is worth ~US$15 billion a year and growing.

UBI’s core technology is a disposable, multi-layer test strip, which incorporates a proprietary electrochemical sensing system that rapidly and accurately measures biomarkers in the blood.  This technology offers speed, ease of use, reliability and accuracy at a low cost.

UBI has partnered with global healthcare company Siemens Healthcare to develop the Xprecia StrideTM blood coagulation analyser, launched in December 2014,  to help patients taking the anti-coagulant drug Warfarin manage their medication.

UBI has also developed a blood glucose monitoring product that is being commercialised globally by LifeScan, Inc. (a Johnson & Johnson company) under the OneTouch® Verio® brand.

UBI's innovative electrochemical sensor platform is being applied to a range of other medical diagnostic applications.